Amyloid-β Peptides in Plasma and Cognitive Decline After 1 Year Follow-Up in Alzheimer's Disease Patients
Amyloid-β Peptides in Plasma and Cognitive Decline After 1 Year Follow-Up in Alzheimer's Disease Patients
复制标题
DOI：
10.3233/jad-2010-100510
复制
发表时间：
2010-01-01
影响因子：
4
通讯作者：
Stellos, Konstantinos
中科院分区：
文献类型：
--
作者：
Laske, Christoph;Sopova, Kateryna;Stellos, Konstantinos
β 淀粉样蛋白 (Aβ) 肽的血浆水平是早期认知障碍和阿尔茨海默病 (AD) 风险的潜在生物标志物。然而，Aβ肽与AD患者认知能力下降速度的关系仍不清楚。在本研究中，我们证明 A beta(1-42) 血浆水平与认知能力下降速度显着相关，并且与认知能力下降缓慢（MMSE 分数下降）的 AD 患者相比，认知能力下降较快的 AD 患者（简易精神状态检查 (MMSE) 评分下降 >= 5/年；n = 12）显着升高。
Plasma levels of amyloid-beta (A beta) peptides are potential biomarkers of early cognitive impairment and of Alzheimer's disease (AD) risk. However, the association of A beta peptides with the rate of cognitive decline in AD patients is still unclear. In the present study we demonstrate that A beta(1-42) plasma levels show a significant correlation with the rate of cognitive decline and are significantly increased in AD patients with fast cognitive decline (decrease of Mini-Mental Status Examination (MMSE) score >= 5/year; n = 12) compared to AD patients with slow cognitive decline (decrease of MMSE score